Please assess the completion status of the following clinical trial:

Trial Title: Afatinib Osimertinib Sequencing NIS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)~* The tumour harbours common EGFR mutations (Del19, L858R) at start of first-line treatment~* Patients who initiated second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry, AND who were treated with afatinib (Gi(l)otrif®) in the first-line~* Patients treated with osimertinib within an EAP/CUP or regular clinical practice~* Age ≥ 18 years~* Signed and dated written informed consent per regulations (Exemption of a written informed consent for NIS based on existing data in countries per local regulations and legal requirements)~Exclusion Criteria:~* Patients who received drug(s) other than osimertinib as the second-line treatment and/or patients who received drug(s) other than afatinib (Gi(l)otrif®) as the first-line treatment~* Patients with active brain metastases at start of treatment (either afatinib/Gi(l)otrif® or osimertinib)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with EGFR mutation-positive NSCLC (Type: None): (Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)

Based on this trial design, predict the completion outcome and termination type (if applicable).